The Impact of High-dose Sodium Selenite Therapy on Bcl-2 Expression in Adult Non-Hodgkin’s Lymphoma Patients: Correlation with Response and Survival

被引：0
作者：
Inas A. Asfour
Manal Fayek
Soha Raouf
Marize Soliman
Hany M. Hegab
Hosam El-Desoky
Rehab Saleh
Mohamed A. R. Moussa
机构：
[1] Ain Shams University Hospital,Clinical Hematology and Bone Marrow Transplantation Unit, Department of Internal Medicine
[2] Ain Shams University,Department of Clinical Pathology, Faculty of Medicine
来源：
Biological Trace Element Research | 2007年 / 120卷
关键词：
Sodium selenite; Bcl-2; Non-Hodgkin’s lymphoma; Overall survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The present study was undertaken to explore the effect of administration of high doses of sodium selenite on the expression of Bcl-2 in patients with non-Hodgkin’s lymphoma (NHL). Fifty patients with newly diagnosed NHL were randomly divided into two groups. Group A-I received standard chemotherapy whereas group A-II received adjuvant sodium selenite 0.2 mg kg−1 day−1 for 30 days in addition to chemotherapy. Enzyme-linked immunosorbent assay was used to assess Bcl-2 at the time of diagnosis and after therapy in the two groups. Sodium selenite administration resulted in significant decline of Bcl-2 level after therapy in group A-II (8.6 ± 6.9 ng/ml vs 3 6.9 ± 7.9 ng/ml, P < 0.05). Also, complete response reached 60% in group A-II compared to 40% in group A-I. Significant increase in CD4/CD8 ratio was noticed in group A-II compared to group A-I after therapy (1.45 ± 0.36 vs 1.10 ± 0.28 p 0.04). Overall survival time in months was significantly longer in complete remission patients in group A-II (21.87 ± 1.41) compared to group A-I (19.70 ± 1.95) (p = 0.01). It is concluded that sodium selenite administration at the dosage and duration chosen acts as a downregulator of Bcl-2 and improves clinical outcome.
引用
收藏
页码：1 / 10
页数：9
相关论文
共 82 条
  • [1] Jemal A.(2004)Cancer statistics Cancer J Clin 54 8-29
  • [2] Tiwari R.C.(2005)Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology Ann Hematol 84 1-12
  • [3] Murray T.(2004)Improving second-line therapy in aggressive non-Hodgkin’s lymphoma Semin Oncol 31 12-16
  • [4] Ghafoor A.(2004)New treatment approaches to indolent non-Hodgkin’s lymphoma Semin Oncol 31 27-32
  • [5] Samuels A.(2003)Ways of dying: multiple pathways to apoptosis Gene Dev 17 2481-2495
  • [6] Ward E.(2004)Bcl-2-related genes in lymphoid neoplasia Int J Hematol 80 205-209
  • [7] Thun M.J.(1988)Selenium in foods Adv Food Res 32 85-82
  • [8] Muller AM(2006)Attenuation of LDL receptor gene expression by selenium deficiency during hypercholesterolemia Mol Cell Biochem 282 75-1467S
  • [9] Ihorst G(2003)Selenium deficiency and viral infection J Nutr 133 1463S-3576
  • [10] Mertelsmann R(2002)How selenium has altered our understanding of the genetic code Mol Cell Biol 22 3565-258
123456789